Is CapsoVision going out of business?

CapsoVision, Inc (CV) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

CapsoVision, Inc (CV) scores 16 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 2088.65% (YoY)

Five questions, kept separate

Survival - Fragile

Runway cannot be estimated from the available cash and cash-flow fields. Adjusted shares outstanding increased 2088.7% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

7% burn burden support a reasonable pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 2088.65% (YoY)
• FCF margin: -169.35%
• Debt / Equity: 0.05x
• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -136.33%
• Revenue growth YoY: 9.89% (YoY)
• Cash Burn Deceleration: -81.97% QoQ improvement (Worsening)
• Price / Earnings: Unprofitable (see Valuation)
• Operating leverage: -355.7%
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-18.

Price as of 2026-09-26.